Skip to main content

Industry News

 

Clinical courses

  • Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

    Takeda and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs). These doses will ultimately be made available for procurement by governments in endemic countries by 2030 at the latest to support National Immunization Programs.

  • Roche Pharma launches ocrelizumab in India after six years of global release

    Roche Pharma launches ocrelizumab in India, six years after global release. Ocrelizumab is an FDA-approved CD20-directed humanized monoclonal antibody indicated to treat adult patients with primary progressive or relapsing multiple sclerosis.

  • Lykos Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for MDMA-Assisted Therapy for PTSD

    Lykos Therapeutics a company dedicated to transforming mental healthcare, announced that the U.S. Food and Drug Administration has accepted its new drug application for midomafetamine capsules used in combination with psychological intervention, which includes psychotherapy (talk therapy) and other supportive services provided by a qualified healthcare provider for individuals with post-traumatic stress disorder (PTSD). The FDA has granted the application priority review and has assigned a Prescription Drug User Fee Act target action date of August 11, 2024.

  • NIHR awards 7m Euro to the University of Birmingham to provide strategic leadership for its Research Support Service

    The NIHR has selected the University of Birmingham to run the National Collaborative for its Research Support Service (RSS) from 1 February 2024.

    The RSS was launched on 1 October 2023. The service provides expert research design, methodological support, advice, and collaboration to all researchers in England throughout the pre- and post-application/research process, regardless of geographic location and research interest.

  • BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

    BioNTech SE a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, and Autolus Therapeutics plc a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations. In connection with the strategic collaboration, the companies entered into a license and option agreement and a securities purchase agreement.

  • Novartis to acquire MorphoSys AG

    Novartis announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG, a Germany-based, global biopharmaceutical company developing innovative medicines in oncology.

  • Zydus Lifesciences launches Rexigo

    Zydus Lifesciences Ltd., a global innovation driven healthcare company announced that it has launched Relugolix under the brand name, Rexigo™. This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India. Though Relugolix was available in developed countries since the last four years, patients in India did not have access to it. With this launch, Zydus brings both access to a critical therapy and also makes it affordable at a cost of Rs.

  • Glenmark partners with Pfizer to launch Abrocitinib in India

    Pfizer and Glenmark Pharmaceuticals Ltd have joined hands to launch abrocitinib, a first of its kind oral advanced systemic treatment for moderate‐to‐severe atopic dermatitis (AD), in India. Developed by Pfizer, abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India and is approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.

  • Siemens Healthineers with IISc opens AI lab for precision medicine

    Medtech giant Siemens Healthineers has teamed up with the Indian Institute of Science (IISc) to launch a collaborative laboratory in Bangalore focused on AI in precision medicine. Healthineers will invest 10 million INR in the partnership over the next five years.

  • HPCI Exhibition & Conference 2024

    HPCI Exhibition & Conference 2024 was held on 18 and 19 January, 2024 at Jio World Convention Centre, BKC, Mumbai. It was organised by ExpoNova Exhibitions & Conferences (India) Pvt. Ltd. It is the only event in India focused on raw materials and techniques for the formulation of cosmetic and cleaning products. It is indeed a place where industry meets, discovers new ingredient and technology, learns about various innovation. Companies from all over India as well as overseas participated and there was something for everyone.

Subscribe to Industry News